WisdomTree U.S. ESG Fund (RESP)
- Previous Close
50.67 - Open
50.92 - Bid --
- Ask --
- Day's Range
50.65 - 50.94 - 52 Week Range
42.22 - 50.94 - Volume
18,661 - Avg. Volume
4,072 - Net Assets 66M
- NAV 50.77
- PE Ratio (TTM) 20.77
- Yield 1.33%
- YTD Daily Total Return 3.26%
- Beta (5Y Monthly) 0.97
- Expense Ratio (net) 0.28%
The fund is actively managed using a model-based approach and seeks to achieve its investment objective by investing primarily in U.S. equity securities of companies that exhibit the highest potential for returns based on proprietary measures of fundamental factors and technical factors, as well as favorable environmental, social, and governance (“ESG”) characteristics. The adviser primarily uses a proprietary multi-factor model to select the fund’s investments. The fund is non-diversified.
WisdomTree
Fund Family
Large Blend
Fund Category
66M
Net Assets
2007-02-23
Inception Date
Performance Overview: RESP
Trailing returns as of 2/15/2024. Category is Large Blend.
People Also Watch
Holdings: RESP
Top 10 Holdings (27.79% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: RESP
RMD: Raising target price to $157.00
RESMED INC has an Investment Rating of SELL; a target price of $157.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRMD: Raising target price to $153.00
RESMED INC has an Investment Rating of SELL; a target price of $153.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetRMD: Raising target price to $142.00
RESMED INC has an Investment Rating of SELL; a target price of $142.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetHAE: Lowering target price to $89.00
HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $89.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target